-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Generic drugs have important economic and social benefits in reducing medical expenditures, improving the availability of medicines, and improving the level of medical services
.
In recent years, in the context of the development of China's pharmaceutical industry, the generic drug industry has also received great attention and has received key support from the national industrial policy
.
It is understood that in terms of policy, the country has issued a series of documents, such as the "Announcement on Matters Concerning the Quality and Efficacy Consistency Evaluation of Generic Drugs", "Opinions on Deepening the Reform of the Medical Security System", and "Regarding the Development of the Imitation of Chemical Drug Injections".
The Announcement on the Consistency Evaluation of Pharmaceutical Quality and Efficacy, etc.
, have provided a clear and broad market prospect for the development of the generic drug industry, and provided a good production and operation environment for enterprises
.
Among them, it is worth mentioning that in recent years, China has been vigorously promoting the consistency evaluation of the quality and efficacy of generic drugs, which will improve the overall level of the pharmaceutical industry in China, ensure the safety and effectiveness of drugs, and promote the upgrading and structural adjustment of the pharmaceutical industry.
International competitiveness has played an important role
.
At present, in this context, a large number of pharmaceutical companies have also begun to accelerate the promotion of consistency evaluation
.
On November 5th, the NMPA website showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
Data show that somatostatin is a cyclic polypeptide hormone.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated by acute erosive gastritis or hemorrhagic gastritis And other symptoms
.
In 2020, the terminal sales of somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
At present, there are 16 manufacturers of somatostatin for injection in the domestic market.
In addition to Hanyu Pharmaceuticals which has been evaluated, Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biotechnology, and Shanghai Huayuan The supplementary application for the consistency evaluation of the product by 5 companies including the pharmaceutical industry is also under review
.
On the same day, the NMPA website showed that Huiyu Pharmaceutical's Palonosetron Hydrochloride Hydrochloride Injection was approved to market with the generic 4 types of applications, and it was deemed to have passed the consistency evaluation.
.
According to data, Palonosetron Hydrochloride is the second-generation 5-HT3 receptor antagonist.
In 2020, the sales of Palonosetron Injection in China's public medical institutions have exceeded 1.
5 billion yuan
.
It is reported that Palonosetron Hydrochloride is currently one of the few 5-HT3 receptor antagonists approved for the prevention of delayed malignant vomiting
.
On May 24 this year, Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection was also approved for marketing in the UK
.
In general, with the continuous reform of the pharmaceutical market and the continuous expansion of national volume procurement varieties, under the stimulus of huge market capacity, consistency evaluation as a threshold for entering national volume procurement is becoming more and more important
.
The industry believes that it is imperative for generic drug companies to promote consistency evaluation, otherwise they will not only lose the market, they may even be eliminated
.
However, it should be noted that as generic drugs enter the accelerated competition, competition in the pharmaceutical market will become more intense.
If pharmaceutical companies want to remain competitive, they will still be indispensable to work hard on innovation
.
.
In recent years, in the context of the development of China's pharmaceutical industry, the generic drug industry has also received great attention and has received key support from the national industrial policy
.
It is understood that in terms of policy, the country has issued a series of documents, such as the "Announcement on Matters Concerning the Quality and Efficacy Consistency Evaluation of Generic Drugs", "Opinions on Deepening the Reform of the Medical Security System", and "Regarding the Development of the Imitation of Chemical Drug Injections".
The Announcement on the Consistency Evaluation of Pharmaceutical Quality and Efficacy, etc.
, have provided a clear and broad market prospect for the development of the generic drug industry, and provided a good production and operation environment for enterprises
.
Among them, it is worth mentioning that in recent years, China has been vigorously promoting the consistency evaluation of the quality and efficacy of generic drugs, which will improve the overall level of the pharmaceutical industry in China, ensure the safety and effectiveness of drugs, and promote the upgrading and structural adjustment of the pharmaceutical industry.
International competitiveness has played an important role
.
At present, in this context, a large number of pharmaceutical companies have also begun to accelerate the promotion of consistency evaluation
.
On November 5th, the NMPA website showed that Hanyu Pharmaceutical's somatostatin for injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
Data show that somatostatin is a cyclic polypeptide hormone.
Somatostatin for injection is mainly used for acute esophageal varices bleeding; severe acute gastric or duodenal ulcer bleeding, or complicated by acute erosive gastritis or hemorrhagic gastritis And other symptoms
.
In 2020, the terminal sales of somatostatin in public medical institutions in China will exceed 2.
4 billion yuan
.
At present, there are 16 manufacturers of somatostatin for injection in the domestic market.
In addition to Hanyu Pharmaceuticals which has been evaluated, Shandong New Times Pharmaceuticals, Hainan Shuangcheng Pharmaceuticals, Jiangsu Coast Pharmaceuticals, Chengdu Shengnuo Biotechnology, and Shanghai Huayuan The supplementary application for the consistency evaluation of the product by 5 companies including the pharmaceutical industry is also under review
.
On the same day, the NMPA website showed that Huiyu Pharmaceutical's Palonosetron Hydrochloride Hydrochloride Injection was approved to market with the generic 4 types of applications, and it was deemed to have passed the consistency evaluation.
.
According to data, Palonosetron Hydrochloride is the second-generation 5-HT3 receptor antagonist.
In 2020, the sales of Palonosetron Injection in China's public medical institutions have exceeded 1.
5 billion yuan
.
It is reported that Palonosetron Hydrochloride is currently one of the few 5-HT3 receptor antagonists approved for the prevention of delayed malignant vomiting
.
On May 24 this year, Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection was also approved for marketing in the UK
.
In general, with the continuous reform of the pharmaceutical market and the continuous expansion of national volume procurement varieties, under the stimulus of huge market capacity, consistency evaluation as a threshold for entering national volume procurement is becoming more and more important
.
The industry believes that it is imperative for generic drug companies to promote consistency evaluation, otherwise they will not only lose the market, they may even be eliminated
.
However, it should be noted that as generic drugs enter the accelerated competition, competition in the pharmaceutical market will become more intense.
If pharmaceutical companies want to remain competitive, they will still be indispensable to work hard on innovation
.
